Salazar VM

Language: Spanish
References: 14
Page: 165-170
PDF size: 121.28 Kb.

ABSTRACT

Diabetes is a health problem of worldwide level, and Mexico is no exception, the high prevalence in morbidity of this patients generates an increase in the costs of attention; The Diabetic foot syndrome is one of the more frequent causes of complication in diabetic patients and one of its more devastating presentations is Charcot Neuroarthropathy, is an inflammatory condition that affects the foot and ankle with different degrees of osseous destruction and deformity, its cause may be due to traumatism (severe or repeated micro traumatism) or arteriovenous shunts, its incidence goes from 0.8 to 7.5%, and prevalence of 1/700 diabetic patients. The most commonly affected zone is the midfoot according to Brodsky´s classification, and its secondary most frequent deformity is the «Rocker bottom foot». The approach to the patients must be multidisciplinary and the orthopedic treatment is the most important to preserve the extremity, focusing on having a plantigrade foot, free of ulcers and that at the end of the treatment will be able to use commercial footwear. The Gold Standard of conservative treatment are total contact casts, mainly in patients on the acute phase of the disease, stadium 0-2 according to Eichenholtz. The treatment with this type of casts goes from 9 to 16 weeks up to 10 months in accordance to the presentation of the disease. Another type of conservative treatments consists on prefabricated boots, pharmacologic treatment and the adaptation of some orthotic devices.

REFERENCES

1. Informe Mundial sobre la Diabetes, Organización Mundial de la Salud, 2016.

2. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 (ESANUT MC 2016), Secretaría de Salud.

3. Beneit J. El síndrome del pie diabético, el modelo de la Clínica Podológica de la Universidad Complutense de Madrid, lección inaugural Curso Académico 2010-2011, Madrid 2010.

4. Eloesser L. On the nature of neuropathic affections of the joints. Am Surgery. 1917; 66: 201-207.

5. Armstrong D, Frykberg R. Classifying diabetic foot surgery: toward a rational definition. Diabet Med. 2003; 20: 329-331.

6. Del Castillo-Tirado R, Fernández J, Del Castillo Tirado F. Guía de práctica clínica en el pie diabético. Archivos de Medicina. 2014; 10 (2): 1-17.

7. Petrova N, Edmonds M. Conservative and pharmacologic treatments for the diabetic Charcot foot. Clin Podiatric Med Surg. 2017; 34 (1): 15-24.

8. Aguilera CC, Povedano J, García A. Neuroartropatía de Charco. Reumatol Clin. 2005; 1 (4): 225-227.

9. Schinca N, Álvarez J. Artropatía neuropática o pie de Charcot. Biomedicina. 2012; 7 (1): 44-50.

10. Caldiño I, Rojas D, Esperon R. Artropatía de Charcot: un método para su tratamiento , seguimiento a cinco años. Artículo original. Acta Ortop Mex. 2017; 31 (2): 67-74.

11. Rios R, Martin-Oliva X, Santamaría-Fumas A, Domínguez-Sevilla A, López-Capdevila L, Vilá y Rico J. Treatment algorithm for Charcot foot and surgical technique with circular external fixation. Acta Ortop Mex. 2018; 32 (1): 7-12.

12. López E, Parra P, Vázquez J. La neuroartropatía de Charcot en el pie diabético, artículo de revisión. Acta Ortopédica Mexicana. 2016; 30 (1): 33-45.

13. Pasquier J, Thomas B. Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclast cell induction. Sci Rep. 2017; 7 (1): 16450.

14. Piaggessi A, Goretti C, Iacopi E. Comparison of removable and irremovable walking boot to totalcontact casting in offloading the neuropathic Diabetic Foot Ulceration. Foot Ankle Int. 2016; 37 (8): 855-861.